Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,418 active trials60 approved drugs271 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,888 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,375)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01421667 | A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Phase 2 | 176 | Seagen Inc.INDUSTRY | 2 | Nov 28, 2016 | clinicaltrials |
| NCT00996593 | Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab | completed | Phase 2 | 43 | GlaxoSmithKlineINDUSTRY | 0 | Nov 23, 2016 | clinicaltrials |
| NCT00683046 |
| T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies |
| completed |
| Phase 2 |
| 204 |
| University of ChicagoOTHER |
| 1 |
| Nov 22, 2016 |
| clinicaltrials |
| NCT00378209 | Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma | completed | Phase 2 | 65 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 17, 2016 | clinicaltrials |
| NCT00656084 | Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell | completed | Phase 2 | 16 | US Oncology ResearchINDUSTRY | 0 | Nov 3, 2016 | clinicaltrials |
| NCT01388959 | A Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Non-Hodgkin's Lymphoma | completed | Phase 2 | 40 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01392716 | A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma | completed | Phase 2 | 48 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT02011113 | Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma | completed | Phase 2 | 36 | Celgene CorporationINDUSTRY | 1 | Nov 1, 2016 | clinicaltrials |
| NCT00891618 | Acupuncture for Chemo-Induced Peripheral Neuropathy | completed | Phase 2 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2016 | clinicaltrials |
| NCT00025662 | Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | completed | Phase 2 | 23 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Oct 28, 2016 | clinicaltrials |
| NCT00634179 | A Phase I/II Trial of VR-CHOP in Lymphoma Patients | completed | Phase 1 / Phase 2 | 37 | Emory UniversityOTHER | 1 | Oct 27, 2016 | clinicaltrials |
| NCT02471820 | Lenalidomide & Adriamycin & Dexamethasone (RAD) in Newly Diagnosed, Multiple Myeloma Patients(RAD) | completed | Phase 2 | 45 | Meletios A. DimopoulosOTHER | 1 | Oct 17, 2016 | clinicaltrials |
| NCT00779922 | Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function | completed | Phase 2 | 39 | Poitiers University HospitalOTHER | 1 | Oct 11, 2016 | clinicaltrials |
| NCT00862719 | Sitagliptin Umbilical Cord Blood Transplant Study | completed | Phase 2 | 29 | Indiana UniversityOTHER | 1 | Oct 7, 2016 | clinicaltrials |
| NCT00607854 | Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)(ZEVALLO) | completed | Phase 2 | 31 | University Hospital, BordeauxOTHER | 1 | Oct 5, 2016 | clinicaltrials |
| NCT00580372 | UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple Myeloma | completed | Phase 2 | 231 | University of ArkansasOTHER | 1 | Sep 20, 2016 | clinicaltrials |
| NCT01113632 | Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 77 | SCRI Development Innovations, LLCOTHER | 1 | Sep 20, 2016 | clinicaltrials |
| NCT00798096 | Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma | completed | Phase 2 | 18 | Rigel PharmaceuticalsINDUSTRY | 2 | Sep 19, 2016 | clinicaltrials |
| NCT00800839 | Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide | completed | Phase 2 | 56 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 19, 2016 | clinicaltrials |
| NCT01015248 | Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma | completed | Phase 2 | 60 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Sep 7, 2016 | clinicaltrials |
| NCT00047788 | Efficacy Study of ZD6474 to Treat Multiple Myeloma Cancer | completed | Phase 2 | 30 | Genzyme, a Sanofi CompanyINDUSTRY | 2 | Aug 24, 2016 | clinicaltrials |
| NCT01701076 | Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma(BRd) | completed | Phase 2 | 50 | Cantonal Hospital of St. GallenOTHER | 1 | Aug 24, 2016 | clinicaltrials |
| NCT00786851 | Salvage Treatment With Lenalidomide and Dexamethaosne (LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL) | completed | Phase 2 | 33 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 17, 2016 | clinicaltrials |
| NCT01319422 | Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma | completed | Phase 2 | 40 | Yale UniversityOTHER | 1 | Aug 11, 2016 | clinicaltrials |
| NCT01523847 | A Multi-centre Study of MBVD in Elderly and/or Cardiopathic Patients Affected by Hodgkin's Lymphoma (HL)(HD0803) | completed | Phase 2 | 50 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 4, 2016 | clinicaltrials |
| NCT00117156 | Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma | completed | Phase 2 | 26 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 1, 2016 | clinicaltrials |
| NCT00133367 | Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus | completed | Phase 2 | 32 | Massachusetts General HospitalOTHER | 1 | Jul 25, 2016 | clinicaltrials |
| NCT00407303 | Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL) | completed | Phase 1 / Phase 2 | 24 | Gemin XINDUSTRY | 1 | Jul 21, 2016 | clinicaltrials |
| NCT00533923 | Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders | completed | Phase 2 | 25 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jul 18, 2016 | clinicaltrials |
| NCT00028600 | Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 2 | 60 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 4, 2016 | clinicaltrials |
| NCT00053196 | Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer | completed | Phase 2 | 82 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 1, 2016 | clinicaltrials |
| NCT00578942 | Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath | completed | Phase 2 | 48 | David Rizzieri, MDOTHER | 1 | Jun 24, 2016 | clinicaltrials |
| NCT00540644 | Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 70 | Attaya SuvannasankhaOTHER | 1 | Jun 21, 2016 | clinicaltrials |
| NCT00861250 | Assessment of Molecular Remission by ASO-qPCR After Bortezomib-dexamethasone (Vel/Dex) Followed by ASCT | completed | Phase 2 / Phase 3 | 47 | Tampere University HospitalOTHER | 1 | Jun 17, 2016 | clinicaltrials |
| NCT01446562 | Y90 Ibritumomab Tiuxetan Post R-CHOP Chemotherapy for Advanced Stage Follicular Lymphoma(ZEVISS) | completed | Phase 2 | 34 | Sunnybrook Health Sciences CentreOTHER | 1 | Jun 17, 2016 | clinicaltrials |
| NCT01079936 | Lenalidomide and High-Dose Melphalan | completed | Phase 1 / Phase 2 | 61 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 6, 2016 | clinicaltrials |
| NCT01599949 | A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy | completed | Phase 2 | 120 | Janssen Research & Development, LLCINDUSTRY | 9 | Jun 1, 2016 | clinicaltrials |
| NCT01286077 | Velcade Consolidation Bone Study | completed | Phase 2 | 106 | Janssen-Cilag International NVINDUSTRY | 8 | May 30, 2016 | clinicaltrials |
| NCT01034553 | Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 26 | Mayo ClinicOTHER | 1 | May 25, 2016 | clinicaltrials |
| NCT01274533 | Lenalidomide in HTLV-1 Adult T-Cell Leukemia | completed | Phase 2 | 4 | Columbia UniversityOTHER | 1 | May 23, 2016 | clinicaltrials |
| NCT01562990 | Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse | completed | Phase 1 / Phase 2 | 11 | The Lymphoma Academic Research OrganisationOTHER | 2 | May 23, 2016 | clinicaltrials |
| NCT01376401 | Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 60 | PETHEMA FoundationOTHER | 1 | May 17, 2016 | clinicaltrials |
| NCT00406978 | Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma Patients(MPTD) | completed | Phase 1 / Phase 2 | 24 | Silvio AimeOTHER | 1 | May 10, 2016 | clinicaltrials |
| NCT00961467 | RMPT for Relapsed/Refractory Multiple Myeloma(RMPT) | completed | Phase 2 | 44 | Fondazione EMN Italy OnlusOTHER | 1 | May 10, 2016 | clinicaltrials |
| NCT00833833 | MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 259 | Celgene CorporationINDUSTRY | 2 | Apr 27, 2016 | clinicaltrials |
| NCT02337595 | Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation(45RA_NEG_DLI) | completed | Phase 1 / Phase 2 | 30 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Apr 22, 2016 | clinicaltrials |
| NCT00831597 | Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma(904) | completed | Phase 2 | 61 | PharmatechINDUSTRY | 1 | Apr 19, 2016 | clinicaltrials |
| NCT00250926 | Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia | completed | Phase 2 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 8, 2016 | clinicaltrials |
Data updated 24 days agoSource updated Nov 28, 2016source: clinicaltrials